Kringle Pharma,Inc. (4884) Cash flow
Market cap
¥2.8B
P/E ratio
-2.3x
Kringel Pharma develops treatments for rare diseases like spinal cord injury and ALS using recombinant human HGF protein technology for medical institutions and pharma partners.
| 2018/09 | 2019/09 | 2020/09 | 2021/09 | 2022/09 | 2023/09 | 2024/09 | 2025/09 | |
| Cash from operations | -202 | -339 | -146 | -561 | 16 | -689 | -661 | -756 |
| Cash from investing | 0 | - | - | - | -254 | -121 | -121 | -154 |
| Repurchases of common stock | - | - | - | -0 | -0 | - | -0 | -0 |
| Cash from financing | 199 | - | 2,083 | 596 | 603 | 69 | 838 | 84 |